Merck Dirección

Dirección controles de criterios 2/4

Merck's El consejero delegado es Rob Davis , nombrado en Apr 2021, tiene un mandato de 2.67 años. la remuneración anual total es $18.65M , compuesta por 8.2% salario y 91.8% primas, incluidas acciones y opciones de la empresa. posee directamente 0.011% de las acciones de la empresa, por valor de €26.31M . La antigüedad media del equipo directivo y del consejo de administración es de 2.7 años y 5.3 años respectivamente.

Información clave

Rob Davis

Chief Executive Officer (CEO)

US$18.7m

Compensación total

Porcentaje del salario del CEO	8.2%
Permanencia del CEO	3yrs
Participación del CEO	0.01%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rob Davis en comparación con los beneficios de Merck?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

Compensación vs. Mercado: Rob($USD18.65M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD4.53M).

Compensación vs. Ingresos: Robha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Rob Davis (56 yo)

3yrs

Permanencia

US$18,650,094

Compensación

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Davis	Chairman	3yrs	US$18.65m	0.014% $ 41.2m
Caroline Litchfield	Executive VP & CFO	3yrs	US$5.70m	0.0020% $ 6.0m
Jennifer Zachary	Executive VP & General Counsel	6yrs	US$5.90m	0.0011% $ 3.4m
Dean Li	Executive VP & President of Merck Research Laboratories	6.4yrs	US$7.77m	0.0018% $ 5.5m
Chirfi Guindo	Senior VP & Chief Marketing Officer of Human Health	1.8yrs	US$13.94m	0.00081% $ 2.4m
Dalton Smart	Senior VP of Finance	less than a year	sin datos	0.00011% $ 329.3k
David Williams	Executive VP and Chief Information & Digital Officer	no data	sin datos	0.00078% $ 2.3m
Peter Dannenbaum	Vice President of Investor Relations	4.7yrs	sin datos	sin datos
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	3yrs	sin datos	0.00020% $ 598.7k
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	2.7yrs	sin datos	sin datos
Betty Larson	Chief Human Resources Officer	no data	sin datos	sin datos
Richard DeLuca	Executive VP & President of Merck Animal Health	12.6yrs	US$6.84m	0.0054% $ 16.2m

3.0yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: 6MKEl equipo directivo de la empresa se considera experimentado (2.7 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Davis	Chairman	2.8yrs	US$18.65m	0.014% $ 41.2m
Peter Wendell	Independent Director	20.6yrs	US$370.00k	0.000040% $ 119.7k
Pamela Craig	Independent Director	8.6yrs	US$372.50k	0.000070% $ 209.6k
Patricia Russo	Independent Director	28.6yrs	US$360.00k	0.00052% $ 1.6m
Thomas Glocer	Independent Lead Director	16.4yrs	US$400.00k	0.00020% $ 598.7k
Risa Lavizzo-Mourey	Independent Director	3.9yrs	US$353.50k	0.000040% $ 119.7k
Inge Thulin	Independent Director	6.1yrs	US$340.00k	0% $ 0
Stephen Mayo	Independent Director	3.1yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	4.1yrs	US$350.00k	0.000020% $ 59.9k
Christine Seidman	Independent Director	4.1yrs	US$377.00k	0% $ 0
Paul Rothman	Independent Director	8.6yrs	US$425.00k	0% $ 0
Mary Coe	Independent Director	5.1yrs	US$350.00k	0% $ 0

5.6yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 6MK se considera experimentada (5.3 años de antigüedad promedio).

Merck Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Merck & Co., Inc., Annual General Meeting, May 28, 2024

Executive VP & General Counsel recently sold €3.5m worth of stock

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Insider recently sold €4.3m worth of stock

Recent updates

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Executive VP & General Counsel recently sold €3.5m worth of stock

Full year 2023 earnings released: EPS: US$0.14 (vs US$5.73 in FY 2022)

Third quarter dividend of US$0.77 announced

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Upcoming dividend of US$0.77 per share at 2.8% yield

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Merck & Co., Inc. (NYSE:MRK) entered into definitive agreement to acquire an unknown stake in Caraway Therapeutics, Inc. from AbbVie Ventures, Inc., SV Health Investors, LLC,Dementia Discovery LP, Amgen Ventures and Eisai Innovation Inc. for $610 million.

FDA Approves Merck’s KEYTRUDA (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck Receives Positive Eu CHMP Opinion for Keytruda (Pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

New minor risk - Insider selling

Insider recently sold €4.3m worth of stock

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad